Compare NRSN & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRSN | VTGN |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | Israel | United States |
| Employees | 16 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 24.1M |
| IPO Year | N/A | 2014 |
| Metric | NRSN | VTGN |
|---|---|---|
| Price | $0.81 | $0.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $8.50 | $0.90 |
| AVG Volume (30 Days) | 103.3K | ★ 644.7K |
| Earning Date | 03-31-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | $583.67 | $353.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $0.43 |
| 52 Week High | $2.60 | $5.14 |
| Indicator | NRSN | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.96 | 50.74 |
| Support Level | $0.68 | $0.57 |
| Resistance Level | $0.86 | $0.66 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 77.56 | 57.92 |
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.